Use of the closure device in patient with percutaneous transfemoral aortic valve replacement

Use of the closure device in patient with percutaneous transfemoral aortic valve replacement - Closure device-TAVR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030588

Enrollment

250

Registered

2022-11-09

Start date

2020-01-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIGH GRADE AORTIC VALVE STENOSIS

Interventions

Group 1: Manta Device Group 2: Prostar Device

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient scheduled for treatment with the TAVR device 2. Decision to use the Manta or the Prostar closure device on a clinical base by the treating physician 3. Signed informed consent

Exclusion criteria

Exclusion criteria: Male or female aged < 18 Pregnant and lactating females Patient has been committed to an institution by legal or regulatory order

Design outcomes

Primary

Measure	Time frame
Feasibility and Safety of the closure device in TAVR patients	—

Countries

Germany

Contacts

Public ContactGaby Heuer

UKA

gheuer@ukaachen.de00492418035881

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026